A new approach for analysing patient compliance

Article

A gap analysis approach may be preferable to Kaplan-Meier survival curves for analysing patient persistence with prescribed medications.

A gap analysis approach may be preferable to Kaplan-Meier survival curves for analysing patient persistence with prescribed medications, according to a report published in the August issue of the American Journal of Ophthalmology.

Paul P. Lee and colleagues from the Eye Center at Duke University, North Carolina, USA conducted a retrospective study of prescription refill patterns. Patients with prescriptions for 2.5 ml bottles of latanoprost, travoprost and bimatoprost were identified from a retail pharmacy database and were followed-up for 12 months. Three separate analyses defined gaps in therapy as spans in excess of 45, 60 or 120 days without a refill for the same medication. Patients were categorised by the number of gaps in therapy and the cumulative length of gaps. A Kaplan-Meier analysis was conducted using a 120-day allowable refill period.

The results showed that, for refill periods of 45, 60 and 120 days, 10.6%, 28.6% and 77.5% of patients, respectively, had no gaps in therapy and that 32.6%, 53.4% and 86.5%, respectively, had 30 days or fewer off therapy in a 12-month period. According to the 45-day threshold analysis, 50.7% of subjects had three or more gaps versus 18.5% in the 60-day analysis and none in the 120-day analysis. The Kaplain-Meier curve demonstrated that 88.6% and 76.1% of subjects were persistent for 120 days and one year, respectively.

According to the researchers, it would appear that a gap analysis approach to analysing patient compliance is more accurate than using Kaplan-Meier survival curves.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.